Module 4: Routes of Exposure–Inhalation
Recorded On: 01/20/2020
This presentation will begin with an overview of the anatomy, physiology, and function of the respiratory tract, including key species differences that should be considered when interpreting the results of animal inhalation toxicology studies for human risk assessment. Inhalation toxicology studies are technically very challenging; unlike other routes of exposure where the exact dose administered is known, for inhaled studies the given dose needs to be calculated based on a series of measurements, calculations, and assumptions. The design and conduct of these studies will be described, including inhalation exposure systems for different species, inhalation devices and methods of aerosol generation for different physical forms of test substance (nebulizers, metered-dose inhalers and other dry powder generators), understanding and measuring inhaled dose, and common toxicity findings (including irritation, inflammation and hyper/metaplasia). Finally, the use of inhaled toxicity study data for risk assessment will be discussed.
Joanne Kilgour, MSc, PhD, ERT
Consultant Toxicologist
Regulatory Science Associates
Dr. Kilgour is a Consultant Toxicologist at Regulatory Science Associates. She has been an Independent Consultant since 2016, focusing on inhaled and oncology projects. She provides strategic nonclinical toxicology advice to small, medium, and large Pharma on product development from Phase 1 through to marketing authorization. Dr. Kilgour also supports development via program design and management, regulatory document preparation, and representation at regulatory meetings. She has 28 years of product development experience in both Pharma and Agrochemicals (including 10 years at both Syngenta Central Toxicology Laboratory and AstraZeneca). Dr. Kilgour is the Chair of the Association of inhalation toxicologists (AIT) and previous Scientific Meetings and the Secretary and Chair of the Education Subcommittee of the British Toxicology Society. She was previously involved in a cross-industry Working Group on challenges of Alveolar Macrophage findings in Inhaled Drug Development (Forbes, et al, 2014) and is currently leading a Pharma-wide Working Group on Inhaled Biologics, aiming to publish two papers in Toxicologic Pathology in 2020. She is an invited speaker on Inhalation Toxicology at the Birmingham MSc Toxicology Course, ACT Course, Educational Workshop for Regulators at FDA in 2013, and European Chemicals Agency (ECHA) in 2017.